Your browser doesn't support javascript.
loading
Xyloglucan, hibiscus and propolis to reduce symptoms and antibiotics use in recurrent UTIs: a prospective study.
Cai, Tommaso; Tamanini, Irene; Cocci, Andrea; Di Maida, Fabrizio; Caciagli, Patrizio; Migno, Serena; Mereu, Liliana; Tateo, Saverio; Malossini, Gianni; Palmieri, Alessandro; Verze, Paolo; Mirone, Vincenzo; Bjerklund Johansen, Truls E.
Afiliación
  • Cai T; Department of Urology, Santa Chiara Hospital, Trento, Italy.
  • Tamanini I; Department of Urology, Santa Chiara Hospital, Trento, Italy.
  • Cocci A; Department of Urology, University of Florence, Florence, Italy.
  • Di Maida F; Department of Urology, University of Florence, Florence, Italy.
  • Caciagli P; Department of Laboratory Medicine, Santa Chiara Regional Hospital, Trento, Italy.
  • Migno S; Department of Gynaecology & Obstetrics, Santa Chiara Regional Hospital, Trento, Italy.
  • Mereu L; Department of Gynaecology & Obstetrics, Santa Chiara Regional Hospital, Trento, Italy.
  • Tateo S; Department of Gynaecology & Obstetrics, Santa Chiara Regional Hospital, Trento, Italy.
  • Malossini G; Department of Urology, Santa Chiara Hospital, Trento, Italy.
  • Palmieri A; Department of Urology, University of Naples, Federico II, Naples, Italy.
  • Verze P; Department of Urology, University of Naples, Federico II, Naples, Italy.
  • Mirone V; Department of Urology, University of Naples, Federico II, Naples, Italy.
  • Bjerklund Johansen TE; Department of Urology, Oslo University Hospital, Oslo, Norway & Institute of Clinical Medicine, University of Oslo, Norway.
Future Microbiol ; 14: 1013-1021, 2019 08.
Article en En | MEDLINE | ID: mdl-31469009
Aim: To evaluate the efficacy of a medical device containing xyloglucan, hibiscus and propolis in the management of recurrent urinary tract infections (rUTIs). Patients & methods: Sixty-one women affected by rUTIs received this medical device, one capsule a day for 15 days (one cycle every month, for 6 months), in an observational, prospective study. Clinical and microbiological evaluations were performed at baseline and 1, 3 and 6 months from enrolment. Results: At first follow-up, 41 reported a clinical improvement and a return to their clinical status before UTI, while 47 and 51 did so at the second and third follow-up evaluations. A statistically significant clinical improvement was reported at each follow-up visit (quality of life [QoL] 94.2 vs 98.6; QoL 94.1 vs 98.7; QoL 94.2 vs 99.1; p < 0.001). A statistically significant reduction in antibiotic use was reported. Conclusion: This medical device is able to improve quality of life in women with rUTIs, reduce recurrences and antibiotic use.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Própolis / Infecciones Urinarias / Xilanos / Extractos Vegetales / Glucanos / Antiinfecciosos Tipo de estudio: Diagnostic_studies / Observational_studies Idioma: En Revista: Future Microbiol Año: 2019 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Própolis / Infecciones Urinarias / Xilanos / Extractos Vegetales / Glucanos / Antiinfecciosos Tipo de estudio: Diagnostic_studies / Observational_studies Idioma: En Revista: Future Microbiol Año: 2019 Tipo del documento: Article País de afiliación: Italia